DMA
Let not ahead of ourselves. I don't believe we can infer that the marketing rights to Relenza is coming back to Biota.
One thing, Stout said that GSK cannot make money with Relenza, then it would be cheaper to give the marketing rights to Relenza, why hang onto it?
Cheers
Add to My Watchlist
What is My Watchlist?